FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024132020> ?p ?o ?g. }

• W2024132020 endingPage "1895" @default.
• W2024132020 startingPage "1883" @default.
• W2024132020 abstract "The anti-estrogen toremifen-Fc-1157a or 4-chloro-1,2-diphenyl-1-[4-[2(N,N-dimethylamino)ethoxy]-phenyl]-1- butene is now used for the treatment of breast cancer. This drug is extensively metabolized by cytochrome P450 dependent hepatic mixed function oxidase in man, yielding mainly the N-demethyl-(DMTOR), 4-hydroxy-(4OH-TOR) and deamino-hydroxy-(TOR III) toremifene metabolites. The specific forms of cytochrome P450 involved in these oxidation reactions were examined in 32 human liver microsomal preparations previously characterized with respect to their contents of several known P450 enzymes. Toremifene was demethylated with an apparent Km of 124 microM while it was hydroxylated with an apparent Km of 139 microM. The metabolic rates were 71 +/- 56, 13 +/- 9 and 15 +/- 4 pmol/min/mg microsomal protein, respectively, for DMTOR, 4-OH-TOR and TOR III. The N-demethylation activity was strongly correlated with estradiol 2-hydroxylation (r = 0.75), nifedipine oxidation (r = 0.86), tamoxifen N-demethylation (r = 0.73), testosterone 6 beta-hydroxylation (r = 0.78) and erythromycin N-demethylation (r = 0.84), all these monooxygenase activities known to be supported by CYP3A4 isoform. Furthermore, the CYP3A content of liver microsomal samples, measured by western blot analysis using a monoclonal anti-human CYP3A4 antibody, was strongly correlated with DMTOR formation (r = 0.80). Compounds such as cyclosporin, triacetyl-oleandomycin and testosterone inhibited the N-demethylation of toremifene metabolism at 80, 89 and 56% vs control, respectively, while the formation of TOR III was inhibited at 78, 82 and 73% vs control and the 4-hydroxylation pathway was inhibited no more than about 50% vs control. Prior incubation of microsomes with 100 microM gestodene, known to be a selective mechanism-based inhibitor of CYP3A4 in the presence of NADPH, led to 76 +/- 6 and 76 +/- 5% (N = 5 samples) reductions in the N-demethylation and formation of TOR III, respectively. Polyclonal antibody directed against human CYP3A enzymes inhibited formation of DMTOR and TOR III by 60 and 46%, respectively. The metabolism of toremifene was not activated by alpha-naphthoflavone. Finally, the use of yeasts genetically engineered for expression of human P4501A1, 1A2, 2C9 and 3A4 allowed us to demonstrate that DMTOR and TOR III formations are mediated by P4501A and 3A4 enzymes and by contrast these enzymes are not involved in the 4-hydroxylation pathway.(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
• W2024132020 created "2016-06-24" @default.
• W2024132020 creator A5026783868 @default.
• W2024132020 creator A5026815006 @default.
• W2024132020 creator A5028433076 @default.
• W2024132020 creator A5045480042 @default.
• W2024132020 creator A5058833651 @default.
• W2024132020 creator A5082241155 @default.
• W2024132020 date "1994-05-01" @default.
• W2024132020 modified "2023-10-08" @default.
• W2024132020 title "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes" @default.
• W2024132020 cites W1508115080 @default.
• W2024132020 cites W1520965071 @default.
• W2024132020 cites W1526269646 @default.
• W2024132020 cites W1575637830 @default.
• W2024132020 cites W1690359427 @default.
• W2024132020 cites W1933260678 @default.
• W2024132020 cites W1971629719 @default.
• W2024132020 cites W1993263798 @default.
• W2024132020 cites W1996681347 @default.
• W2024132020 cites W1996968257 @default.
• W2024132020 cites W1998266697 @default.
• W2024132020 cites W1999301197 @default.
• W2024132020 cites W2004512624 @default.
• W2024132020 cites W2012232799 @default.
• W2024132020 cites W2012953354 @default.
• W2024132020 cites W2021219604 @default.
• W2024132020 cites W2030488800 @default.
• W2024132020 cites W2051175552 @default.
• W2024132020 cites W2054364537 @default.
• W2024132020 cites W2065516217 @default.
• W2024132020 cites W2073541600 @default.
• W2024132020 cites W2083675642 @default.
• W2024132020 cites W2084082904 @default.
• W2024132020 cites W2086339819 @default.
• W2024132020 cites W2091509247 @default.
• W2024132020 cites W2095313932 @default.
• W2024132020 cites W2100837269 @default.
• W2024132020 cites W2150946709 @default.
• W2024132020 cites W2169290209 @default.
• W2024132020 doi "https://doi.org/10.1016/0006-2952(94)90319-0" @default.
• W2024132020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8204106" @default.
• W2024132020 hasPublicationYear "1994" @default.
• W2024132020 type Work @default.
• W2024132020 sameAs 2024132020 @default.
• W2024132020 citedByCount "81" @default.
• W2024132020 countsByYear W20241320202012 @default.
• W2024132020 countsByYear W20241320202013 @default.
• W2024132020 countsByYear W20241320202014 @default.
• W2024132020 countsByYear W20241320202015 @default.
• W2024132020 countsByYear W20241320202016 @default.
• W2024132020 countsByYear W20241320202017 @default.
• W2024132020 countsByYear W20241320202019 @default.
• W2024132020 countsByYear W20241320202020 @default.
• W2024132020 crossrefType "journal-article" @default.
• W2024132020 hasAuthorship W2024132020A5026783868 @default.
• W2024132020 hasAuthorship W2024132020A5026815006 @default.
• W2024132020 hasAuthorship W2024132020A5028433076 @default.
• W2024132020 hasAuthorship W2024132020A5045480042 @default.
• W2024132020 hasAuthorship W2024132020A5058833651 @default.
• W2024132020 hasAuthorship W2024132020A5082241155 @default.
• W2024132020 hasConcept C104317684 @default.
• W2024132020 hasConcept C109650736 @default.
• W2024132020 hasConcept C11824378 @default.
• W2024132020 hasConcept C121608353 @default.
• W2024132020 hasConcept C126322002 @default.
• W2024132020 hasConcept C134018914 @default.
• W2024132020 hasConcept C150194340 @default.
• W2024132020 hasConcept C181199279 @default.
• W2024132020 hasConcept C185592680 @default.
• W2024132020 hasConcept C190727270 @default.
• W2024132020 hasConcept C202199734 @default.
• W2024132020 hasConcept C2777176818 @default.
• W2024132020 hasConcept C2777637070 @default.
• W2024132020 hasConcept C2781109383 @default.
• W2024132020 hasConcept C526171541 @default.
• W2024132020 hasConcept C530470458 @default.
• W2024132020 hasConcept C55493867 @default.
• W2024132020 hasConcept C62231903 @default.
• W2024132020 hasConcept C71924100 @default.
• W2024132020 hasConcept C86803240 @default.
• W2024132020 hasConcept C87644729 @default.
• W2024132020 hasConceptScore W2024132020C104317684 @default.
• W2024132020 hasConceptScore W2024132020C109650736 @default.
• W2024132020 hasConceptScore W2024132020C11824378 @default.
• W2024132020 hasConceptScore W2024132020C121608353 @default.
• W2024132020 hasConceptScore W2024132020C126322002 @default.
• W2024132020 hasConceptScore W2024132020C134018914 @default.
• W2024132020 hasConceptScore W2024132020C150194340 @default.
• W2024132020 hasConceptScore W2024132020C181199279 @default.
• W2024132020 hasConceptScore W2024132020C185592680 @default.
• W2024132020 hasConceptScore W2024132020C190727270 @default.
• W2024132020 hasConceptScore W2024132020C202199734 @default.
• W2024132020 hasConceptScore W2024132020C2777176818 @default.
• W2024132020 hasConceptScore W2024132020C2777637070 @default.
• W2024132020 hasConceptScore W2024132020C2781109383 @default.
• W2024132020 hasConceptScore W2024132020C526171541 @default.
• W2024132020 hasConceptScore W2024132020C530470458 @default.

• next